114 related articles for article (PubMed ID: 22803620)
21. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
22. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
23. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
[TBL] [Abstract][Full Text] [Related]
24. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
Goncalves DP; Laurindo I; Scheinberg MA
J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
[No Abstract] [Full Text] [Related]
25. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
26. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino J; Carmona L
Acta Reumatol Port; 2006; 31(3):201-3. PubMed ID: 17094331
[No Abstract] [Full Text] [Related]
27. [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court].
Sieper J
Z Rheumatol; 2002 Dec; 61(6):688-93. PubMed ID: 12491132
[TBL] [Abstract][Full Text] [Related]
28. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians.
Perlmutter A; Mittal A; Menter A
Br J Dermatol; 2009 Jan; 160(1):8-15. PubMed ID: 19016693
[TBL] [Abstract][Full Text] [Related]
29. Pericardial effusions on anti-TNF therapy for rheumatoid arthritis--a drug side effect or uncontrolled systemic disease?
Edwards MH; Leak AM
Rheumatology (Oxford); 2009 Mar; 48(3):316-7. PubMed ID: 19106166
[No Abstract] [Full Text] [Related]
30. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
Burr ML; Malaviya AP; Gaston JH; Carmichael AJ; Ostör AJ
Rheumatology (Oxford); 2008 May; 47(5):738-9. PubMed ID: 18375402
[No Abstract] [Full Text] [Related]
31. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
[No Abstract] [Full Text] [Related]
32. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
33. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al.
Aparicio AG; Muñoz-Fernández S; Bonilla G; Miralles A; Cerdeño V; Martín-Mola E
Arthritis Rheum; 2003 Jun; 48(6):1764-5; author reply 1765-6. PubMed ID: 12794847
[No Abstract] [Full Text] [Related]
34. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
35. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
36. Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
Teh BW; Street AC; McBryde ES; Denholm JT
J Rheumatol; 2012 Jun; 39(6):1297-8. PubMed ID: 22661422
[No Abstract] [Full Text] [Related]
37. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
[No Abstract] [Full Text] [Related]
38. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris.
Antoniou C; Dessinioti C; Katsambas A; Stratigos AJ
Br J Dermatol; 2007 May; 156(5):1090-1. PubMed ID: 17408391
[No Abstract] [Full Text] [Related]
39. [TNF-alpha inhibitors].
Fain O
Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
[No Abstract] [Full Text] [Related]
40. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
Roos JC; Chilvers ER; Ostor AJ
J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
